Search

Home > Publications > SATVI Research Papers Published

SATVI Research Papers Published

Since its establishment in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) has produced many high impact articles, documenting research findings in international journals and made presentations at a range of international conferences.

View the complete SATVI Bibiography on Pub Med . Click here.

 

2018 Research Outputs

Publications published by SATVI authors in peer-reviewed journals during 2018

  Title Authors Journal
1 Phase 2b Controlled Trial of M72/AS01 Vaccine E
to Prevent Tuberculosis.
Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR. New England Journal of Medicine, 379 (17):1621-634.
2

Prevention of M tuberculosis infection with H4:IC31 vaccine or BCG revaccination.

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT,
Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus, M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team
 and ACS cohort study groups

New England Journal of Medicine, 379 (2):138-
3

Metabolite changes in blood predict the onset of tuberculosis.

Weiner J, Maertzdorf J, Sutherland JS, Duffy FJ,
Thompson E, Suliman S, McEwen G, Thiel B, Parida
SK, Zyla J, Hanekom WA, Mohney RP, Boom WH,
Mayanja-Kizza H, Howe R, Dockrell HM, Ottenhoff
THM, Scriba TJ, Zak DE, Walzl G, Kaufmann SHE & The GC6-74 consortium.
Nature Communications (9):5208.
4 HIV testing uptake among the household contacts of multidrug resistant tuberculosis index cases in eight countries.
Opollo VS, Wu X, Hughes MD, Swindells S, Gupta A,
Hesseling A, Churchyard G, Kim W, Lando R, Dawson R, Mave V, Mendoza A, Gonzales P, Kumarasamy N, Von Groote-Bidlingmaier F, Conradie F, Shenje J, Fontain SN, Garcia Prats A, Asmelash A, Nedsuwan S, Mohapi L, Mngqibisa R, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Mngqibisa R, Garcia-Ferreira AC, Okeyo E, Naina L, Jones L, Smith B, Shah N, and A5300 Study team.
International Journal of Tuberculosis and Lung Disease, 22(12): 1443-1449
5

Safety and immunogenicity of Adenovirus 35  tuberculosis vaccine candidate in adults with active or previous tuberculosis. A randomized trial.

van Zyl-Smit RN, Esmail A, Bateman ME, Dawson R, Goldin J, van Rikxoort E, Douoguih M, Pau MG, Sadoff JC, McClain JB, Snowden MA, Benko J, Hokey DA, Rutkowski KT, Graves A, Shepherd B, Ishmukhamedov S,  Kagina B, Abel B, Hanekom WA, Scriba TJ, Bateman ED.     American Journal of Respiratory and Critical Care Medicine. 2017; 195(9):1171-1180.
6

Prospects for a vaccine to prevent HIV-related tuberculosis.

Nemes E, Scriba TJ, Hatherill M. Current Opinion in HIV AIDS, 13(6): 522-527.
7

Can we predict tuberculosis cure? What tools are available?

Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denkinger CM, Cobelens F. European Respiratory Journal, 52(5).
8

Four-gene Pan-African blood signature predicts progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M,Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K,Downing K, Fisher ML, Valvo J, Parida SK, van der SpuyG, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH,Zak DE, Walzl G; and the GC6-74 and ACS cohort studygroups.

American Journal of Respiratory and Critical Care Medicine, 197 (9).
9

Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M.  
Lancet Respiratory Medicine, 6 (4): 287-298.
10

T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.

Musvosvi M, Duffy D, Filander E, Africa H, Mabwe S,
Jaxa L, Bilek N, Llibre A, Rouilly V, Hatherill M, Albert M,Scriba TJ, Nemes E.

European Respiratory Journal, 51 (3)pii 1800153.

11

Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester  region of the Western Cape province of South Africa.

Grifoni A, Sidney J, Carpenter C, Phillips E, Mallal S,
Scriba TJ, Sette A, Lindestam Arlehamn CS.
Human Immunology, 79 (3): 143-144.
12

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.


Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M.

Tuberculosis (Edinb), 109: 61-68.
13

Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin for infants of Human Immunodeficiency Virus-Infected Mothers: A phase 2 randomized, controlled trial.

Nemes E, Hesseling AC, Tameris M, Mauff K,
Downing K, Mulenga H, Rose P, van der Zalm M,
Mbaba S, Van As D, Hanekom WA, Walzl G, Scriba
TJ
, McShane H, Hatherill M, MVA029 Study team.

Clinical Infectious Disease, 66 (4): 554-563.

14

Using vaccine  immunostimulation/immunodynamic modelling methods to inform vaccine dose decision-making.

Rhodes SJ, Guedj J, Fletcher HA, Lindenstrøm T, Scriba TJ, Evans TG, Knight GM, White RG.

Nature Partner Journal Vaccines, 3:36.

15

A multi-cohort study of the immune factors associated with M tuberculosis infection outcomes.

Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ,
Darboe F, Penn-Nicholson A, Rozot V, Nemes E,
Malherbe ST, Ronacher K, Walzl G, Hanekom W,
Davis MM, Winter J, Chen X, Scriba TJ, Khatri P,
Chien YH.
Nature, 560 (7720): 644-648.
16

Diagnostic challenge of tuberculosis heterogeneity.

Nemes E, Meermeier EW, Scriba TJ, Walzl G,
Malherbe ST, Lewinsohn DM.

Seminar Respiratory Critical Care Medicine, 39 (3): 286 - 296.
17

A Diverse lipid antigen-specific TCR repertoire is clonally expanded during active tuberculosis.

De Witt WS, Yu KKQ, Wilburn DB, Sherwood A, Vignali M, Day CL, Scriba TJ, Robins HS, Swanson WJ, Emerson RO, Bradley PH, Seshadri.

Journal of Immunology, 201 (3): 888-896.

18

The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis.

Jhilmeet N, Lowe DM, Riou C, Scriba TJ, Coussens A, Goliath R, Wilkinson RJ, Wilkinson KA.

PLoS One, 13 (12) e0209516.

19

Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria.

Graustein AD, Misch EA, Musvosvi M, Shey M, Shah JA, Seshadri C, Aguoju A, Bowman K, Mulenga H, Veldsman A, Hanekom W, Hatherill M, Scriba TJ, Hawn TR. PLoS One, 13(12): e0208940.
20 Allelic resolution NGS HLA typing of 7. Class I and Class II loci and haplotypes in Cape Town, South Africa. Thorstenson YR, Creary LE, Huang H, Rozot V, Nguyen TT, Babrzadeh F, Kancharla S, Fukushima M, Kuehn R,Wang C, Li M, Krishnakumar S, Mindrinos M, Fernandez, Viña MA, Scriba TJ, Davis MM. Human Immunology, 379 (17), 1621-1634.
  PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells is associated  with Bacterial load in Human Tuberculosis.  Day CL, Abrahams DA, Bunjun R, Stone L, de Kock M, Walzl G, Wilkinson RJ, Burgers WA, Hanekom WA. Frontiers in Immunology, 9:1995.
22 Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination. Hasso-Agopsowicz M, Scriba TJ, Hanekom WA, Dockrell HM, Smith SG.
Scientific Reports, 30;8(1):13086.
23

Integrating non-human primate, human, and mathematical studies to determine the influence of BCG timing on H56 vaccine outcomes.

Joslyn LR, Pienaar E, DiFazio RM, Suliman S,
Kagina BM, Flynn JL, Scriba TJ, Linderman JJ,
Kirschner DE.
Frontiers in Microbiology, 9:1734.
24

WHO preferred product characteristics for new vaccines against tuberculosis.

Schrager LK, Chandrasekaran P, Fritzell BH,
Hatherill M, Lambert PH, McShane H, Tornieporth
N, Vekemans J.
Lancet Infectious Diseases, 18 (8): 828-829.
25 Functional, antigen-specific stem cell memory + (T ) CD4 T Cells are induced by human SCM Mycobacterium tuberculosis infection. Mpande CAM, Dintwe OB, Musvosvi M, Mabwe S, Bilek N, Hatherill M, Nemes E, Scriba TJ SATVI Clinical Immunology Team.
Frontiers of Immunology, 9: 324.
26 Protein kinase C-delta (PKCd), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice. Parihar SP, Ozturk M, Marakalala MJ, Loots DT,
Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges, M, Scriba TJ, Guler R, Brombacher F.
Mucosal Immunology, 11 (2): 579-580.
27 Progress and challenges in TB vaccine development. Voss G, Casimiro D, Neyrolles O, Williams A, Kaufmann SHE, McShane H, Hatherill M, Fletcher HA.
F1000 Research 7:199.
28 Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells Darboe F, Mbandi SK, Thompson EG, Fisher M,
Rodo M, van Rooyen M, Filander E, Bilek N, Mabwe S, Hatherill M
, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team.
Tuberculosis (Edinb), 108:124-126.
29  A serum circulating miRNA signature for short-term risk of progression to active Tuberculosis among household contacts. Duffy FJ, Thompson E, Downing K, Suliman S,
Mayanja-Kizza H, Boom WH, Thiel B, Weiner J,
Kaufmann SHE, Dover D, Tabb DL, Dockrell HM,
Ottenhoff THM, Tromp G, Scriba TJ, Zak DE, Walzl G; GC6-74 Consortium.
Frontiers in Immunology, 9: 661.
30 Cd1b Tetramers identify T-cells that recognize natural and synthetic Diacylated Sulfoglycolipids from Mycobacterium tuberculosis. James CA, Yu KKQ, Gilleron M, Prandi J, Yedulla VR, Moleda ZZ, Diamanti E, Khan M, Aggarwal VK,
Reijneveld JF, Reinink P, Lenz S, Emerson RO, Scriba TJ, Souter MNT, Godfrey DI, Pellicci DG, Moody DB, Minnaard AJ, Seshadri C, Van Rhijn I.

Cell Chemical Biology,19;25 (4): 392-402.
31 Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination. Layton ED, Yu KKQ, Smith MT, Scriba TJ, De Rosa SC,Seshadri C. Journal of Immunological Methods, 458: 44-52.
32 Elevated IgG Responses in infants are associated with reduced prevalence of Mycobacterium tuberculosis infection. Logan E, Luabeya AKK, Mulenga H, Mrdjen D, Ontong C, Cunningham AF, Tameris M, McShane H, Scriba TJ, Horsnell WGC, Hatherill M.
Frontiers in Immunology, 9: 1529.
33 Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals. Schmidt BM, Tameris M, Geldenhuys H, Luabeya A,
Bunyasi E, Hawkridge T, McClain JB, Mahomed H,
Scriba TJ, McShane H, Hatherill M.

Tropical Medical International Health, 23 (1): 63-
68.

34 Comparison of CyTOF assays across sites: Results of a six-center pilot study. Leipold MD, Obermoser G, Fenwick C, Kleinstuber K, Rashidi N, McNevin JP, Nau AN, Wagar LE, Rozot V, B D, Olsen LR, Maecker HT. Journal of Immunological Methods, 453: 37-43.
35 Helen McShane and colleagues reply to Deborah Cohen. McShane H, Hill A, Hatherill M, Tameris M, Shea J,
Ginsberg A.

British Medical Journal, 26; 360:k236.
36 Meeting Report: 5th Global Forum on TB Vaccines, 20-23 February 2018, New Delhi. Atmakuri K, Penn-Nicholson A, Tanner R, Dockrell
HM.
Tuberculosis (Edinb), 113:55-64.
37 Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting. Van der Heijden YF, Abdullah F, Andrade BB,
Andrews JR, Christopher DJ, Croda J, Ewing H,
Haas DW, Hatherill M, Horsburgh CR Jr, Mave
V, Nakaya HI, Rolla V, Srinivasan S, Sugiyono
RI, Ugarte-Gil C, Hamilton C.

Tuberculosis (Edinb). 113:153-162.

38 Clean blood, religion, and moral triage in Tuberculosis vaccine trials. Dixon J, Tameris M.
Medical Anthropology, 10: 1-14.